FDA MUST "INSULATE" PREMARKET REVIEW PROCESS FROM IMPACT OF FDA REFORM LEGISLATION -- REED SMITH SHAW & McCLAY ANALYSIS; HOUSE CONFEREES APPOINTED
This article was originally published in The Gray Sheet
FDA must "insulate" its premarket review process from the potential "distractions" posed by the demands of implementing pending FDA reform legislation, an analysis of the legislation performed by the Washington, D.C. law firm of Reed Smith Shaw & McClay recommends. Noting the numerous regulations, guidances and reports mandated by the measure, the firm says "an unintended short-term effect of the FDA Modernization Act [S 830/HR 1411] may be to slow down the `nuts-and-bolts' application reviews of the agency." The analysis was co-authored by former FDA Associate Commissioner for Legislative Affairs Marc Sheineson.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.